NASDAQ:DRMA Dermata Therapeutics (DRMA) Stock Price, News & Analysis → CBOE shift unlocks new weekend income strategy (From DTI) (Ad) Free DRMA Stock Alerts $0.39 -0.01 (-2.70%) (As of 08:39 AM ET) Add Compare Share Share Today's Range$0.39▼$0.3950-Day Range$0.38▼$0.5252-Week Range$0.37▼$3.93Volume2,224 shsAverage Volume849,441 shsMarket Capitalization$1.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Dermata Therapeutics alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Dermata Therapeutics Stock (NASDAQ:DRMA)Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Read More DRMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRMA Stock News HeadlinesFebruary 11, 2024 | ca.finance.yahoo.comDermata Therapeutics, Inc. (DRMAW)February 6, 2024 | finance.yahoo.comPresenting on the Emerging Growth Conference 67 Day 1 on February 7 Register NowMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…February 4, 2024 | morningstar.comDermata Therapeutics Inc DRMAFebruary 1, 2024 | finance.yahoo.comDermata to Present at the Emerging Growth Conference on February 7, 2024January 7, 2024 | msn.comDermata stock soars on patent issuance, partnership talksJanuary 5, 2024 | msn.comDow Turns Lower; ISM Services PMI Falls In DecemberJanuary 5, 2024 | msn.comWhy Is Aesthetic Skin Conditions-Focused Dermata Therapeutics Stock Trading Higher Today?March 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.January 5, 2024 | investorplace.comWhy Is Dermata Therapeutics (DRMA) Stock Up 62% Today?January 4, 2024 | marketwatch.comStocks to Watch: Dermata Therapeutics, Applied Therapeutics, Fusion PharmaceuticalsJanuary 4, 2024 | marketwatch.comDermata Therapeutics Shares Surge 120% on Patent Issued in JapanJanuary 4, 2024 | msn.comWhy Dermata Therapeutics Stock Took Off After-HoursJanuary 4, 2024 | finance.yahoo.comDermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of HyperhidrosisDecember 21, 2023 | finanznachrichten.deDermata Therapeutics: Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 20, 2023 | benzinga.comDermata Therapeutics Stock (NASDAQ:DRMA) Dividends: History, Yield and DatesDecember 20, 2023 | finance.yahoo.comDermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 13, 2023 | thestreet.comDermata Therapeutics Inc.November 16, 2023 | finance.yahoo.comDermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq RulesNovember 16, 2023 | finance.yahoo.comDermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 ProtocolsNovember 10, 2023 | msn.comDermata Therapeutics GAAP EPS of -$0.54November 9, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comDermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne TrialAugust 31, 2023 | finance.yahoo.comDermata to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 11, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsJune 27, 2023 | finance.yahoo.comDermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe AcneJune 13, 2023 | finance.yahoo.comDermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ETSee More Headlines Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DRMA CUSIPN/A CIK1853816 Webwww.dermatarx.com Phone858-800-2543FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.95% Return on Assets-93.59% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book0.22Miscellaneous Outstanding Shares3,540,000Free Float3,206,000Market Cap$1.42 million OptionableNot Optionable Beta0.87 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Gerald T. Proehl (Age 65)Founder, President, CEO & Chairman Comp: $352.92kMr. David F. Hale (Age 75)Co-Founder & Lead Independent Director Comp: $18.12kMs. Kyri K. Van Hoose CPA (Age 45)M.B.A., Senior VP & CFO Comp: $328.75kDr. Christopher J. Nardo M.P.H. (Age 59)Ph.D., Senior VP & Chief Development Officer Comp: $329.92kMr. Sean ProehlSenior Director of Legal & Business DevelopmentDr. Maria Bedoya Toro Munera M.B.A. (Age 72)Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance Comp: $27.04kMore ExecutivesKey Competitors60 Degrees PharmaceuticalsNASDAQ:SXTPSunshine BiopharmaNASDAQ:SBFMCyclacel PharmaceuticalsNASDAQ:CYCCHistogenNASDAQ:HSTOBaudax BioNASDAQ:BXRXView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 218,000 shares on 2/13/2024Ownership: 6.158%View All Institutional Transactions DRMA Stock Analysis - Frequently Asked Questions How have DRMA shares performed in 2024? Dermata Therapeutics' stock was trading at $0.61 on January 1st, 2024. Since then, DRMA shares have decreased by 34.4% and is now trading at $0.40. View the best growth stocks for 2024 here. When is Dermata Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our DRMA earnings forecast. When did Dermata Therapeutics' stock split? Shares of Dermata Therapeutics reverse split before market open on Tuesday, March 14th 2023. The 1-16 reverse split was announced on Tuesday, March 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Dermata Therapeutics IPO? Dermata Therapeutics (DRMA) raised $18 million in an IPO on Friday, August 13th 2021. The company issued 2,571,428 shares at $7.00 per share. Who are Dermata Therapeutics' major shareholders? Dermata Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (6.16%). How do I buy shares of Dermata Therapeutics? Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DRMA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.